Cartesian Therapeutics — Third Quarter 2026 Earnings Summary

Cartesian Therapeutics reported a net loss of $11.5 million for the third quarter of 2026, driven by increased research and development expenses associated with its Phase 3 AURORA trial for myasthenia gravis. The company's lead candidate, Descartes-08, demonstrated deep and durable responses in retreatment data, with a mean 6.6-point reduction in MG-ADL scores at Month 12 and no new safety signals. Phase 3 AURORA trial data is expected in the first quarter of 2027, supporting a planned Biologics License Application filing in mid-2027. As of September 30, 2026, the company held approximately $124.7 million in cash and cash equivalents, which is projected to fund operations through 2028.